00156 LIPPO CHINA RES
- 0.790
- -0.010-1.25%
LIPPO CHINA RES News
Lippo Huarun (00156) announced annual results. Shareholders' losses amounted to HK$146 million, a year-on-year decrease of 47.31%
Lippo China Resources (00156) announced its 2023 annual results, with revenue of HK$739 million, an increase of 21.7 million over the previous year...
LIPPO CHINA RES: FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Lippo China Resources (00156.HK) Profit Alert: Shareholders' consolidated loss is expected to be around HK$140 million in 2023
Glonghui, March 22丨Lippo Huarun (00156.HK) announced that it is anticipated that the Group may record net fair value earnings of approximately HK$20 million in fair value financial instruments for the year ended 31 December 2023, while the year ended 31 December 2022 (the “previous year”) recorded a fair value loss of approximately HK$104 million. According to the company's current data, the board of directors anticipates that the Group may record a comprehensive loss attributable to shareholders of about HK$140 million in the year, compared to a comprehensive loss of HK$278 million in the previous year. The decrease in losses was mainly due to the improvement in the annual performance of the Group's food business
LIPPO CHINA RES: INSIDE INFORMATION ANNOUNCEMENT/PROFIT WARNING
Lippo China Resources (00156.HK) held a board meeting on March 27 to approve annual results
Glonghui, March 15, 丨 Lippo Huarun (00156.HK) announced that the company will hold a board meeting on Wednesday, March 27, 2024 on the 40th floor of Tower 2, Lippo Centre, 89 Queensway, Hong Kong, to (among others) approve the announcement of the comprehensive annual results of the company and its subsidiaries for the year ended 31 December 2023 and consider proposals for a proposed final dividend (if applicable).
Subdued Growth No Barrier To Lippo China Resources Limited (HKG:156) With Shares Advancing 28%
Lippo China Resources Limited (HKG:156) shareholders would be excited to see that the share price has had a great month, posting a 28% gain and recovering from prior weakness. Unfortunately, the ga
Huatai Securities's 24-year Food and Beverage Outlook: Demand Recovery Expectations Are Steady, Focus on Three Main Lines
The Zhitong Finance App learned that Huatai Securities released a research report saying that considering the current internal and external environment, overall demand in the food and beverage sector is expected to recover steadily in '24. Combined with the current low valuation (CS Food and Drink PETTM is in the 9% quartile since 2018) and optimism about the long-term potential of domestic food and beverage consumption, the sector still has medium- to long-term allocation value.
Healthway Medical to Be Delisted This Week
Lippo (HKG:0226) and unit Lippo China Resources (HKG:0156) said in a joint statement that Healthway Medical (SGX:5NG) will be delisted from the Singaporean bourse, effective Wednesday, Nov. 8.
Lippo (00226.HK) and Lippo Huarun (00156.HK): Healthway will be removed from the official listing list of the New Stock Exchange Kelly Board starting November 8
On November 6, Greenway announced that Lippo (00226.HK) and Lippo Huarun (00156.HK) jointly announced that on November 6, 2023, Healthway announced that it will be removed from the official listing list of the Singapore Stock Exchange Kelly Board starting November 8, 2023 at 9:00 a.m. (Singapore time).
Lippo China Resources Announces Singapore Stock Exchange Does Not Oppose Healthway's Delisting
Lippo China Resources (00156) and Lippo (00226) jointly announced that on October 16, 2023, Healthway announced that they had received a letter from the SGX stating that the SGX has no objection to delisting, provided that the following conditions have been met: Healthway makes an immediate announcement on the proposed delisting; and Healthway submits written confirmation that it is unaware of any information that would have a significant impact on investors' decisions that Healthway has not yet published. Healthway announced that the above conditions have been met. After receiving the Singapore Stock Exchange
Lippo China Resources (00156): SGX has no objection to Healthway's delisting
Lippo Huarun (00156) and Lippo (00226) jointly announced on October 1, 2023...
Lippo Says Healthway Medical Delisting Gets Shareholder Nod
Lippo (HKG:0226) and unit Lippo China Resources (HKG0156) said Healthway Medical Corp. shareholders have approved the delisting of Healthway's stock from the Singapore bourse The delisting will take e
LIPPO CHINA RES: 2023 Interim Report
Lippo China Resources Limited's (HKG:156) 28% Share Price Surge Not Quite Adding Up
The Lippo China Resources Limited (HKG:156) share price has done very well over the last month, posting an excellent gain of 28%. Not all shareholders will be feeling jubilant, since the share pric
LIPPO CHINA RES: INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
Lippo China Resources (00156) Profit Warning estimates that the interim shareholders should account for a comprehensive loss of approximately HK$59 million
Lippo China Resources (00156) announced that it expects the Group to be fair for the six months ending June 30, 2023...
LIPPO CHINA RES: INSIDE INFORMATION ANNOUNCEMENT PROFIT WARNING
Lippo China Resources (00156.HK) held a board meeting on August 30 to approve the interim results
Glonghui, August 18, 丨 Lippo China Resources (00156.HK) announced that on Wednesday, August 30, 2023, the company will hold a board meeting on the 40th floor of Tower 2, Lippo Centre, 89 Queensway, Hong Kong to (including) approve the company and its subsidiaries' interim results for the six months ended June 30, 2023 and their publication, and consider the payment of interim dividends (if applicable).
LIPPO CHINA RES: DATE OF BOARD MEETING
Lippo Huarun (00156.HK): The estimated amount of proceeds from the redemption of fund equity redemption is approximately US$243,000
On July 14, 2023, | Lippo Huarun (00156.HK) announced that on July 14, 2023, CEI issued a redemption notice to redeem 150.103 Class A share units in the fund. Based on the fund's unaudited net asset value on June 30, 2023 (that is, the latest information available to CEI), the estimated amount of redemption proceeds is approximately US$243,000 (equivalent to approximately HK$1,900,000). Prior to further redemption, the Group had made previous redemption transactions with the Fund, and the total amount of proceeds was approximately US$4,213,000 (equivalent to approximately
Analysis
Price Target
No Data
